Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Christopher B. Fox
Advertisement
Christopher B. Fox is the lead formulation engineer at the Infections Disease Research Institute
Articles by Christopher B. Fox
Advertisement
Latest Updated Articles
Advertisement
Advertisement